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Abstract
Background/Aims: The epidemiology of Chagas disease, until recently confined to areas of continental Latin America, has
undergone considerable changes in recent decades due to migration to other parts of the world, including Spain. We
studied the prevalence of Chagas disease in Latin American patients treated at a health center in Barcelona and evaluated
its clinical phase. We make some recommendations for screening for the disease.
Methodology/Principal Findings: We performed an observational, cross-sectional prevalence study by means of an
immunochromatographic test screening of all continental Latin American patients over the age of 14 years visiting the
health centre from October 2007 to October 2009. The diagnosis was confirmed by serological methods: conventional in-
house ELISA (cELISA), a commercial kit (rELISA) and ELISA using T cruzi lysate (Ortho-Clinical Diagnostics) (oELISA). Of 766
patients studied, 22 were diagnosed with T. cruzi infection, showing a prevalence of 2.87% (95% CI, 1.6–4.12%). Of the
infected patients, 45.45% men and 54.55% women, 21 were from Bolivia, showing a prevalence in the Bolivian subgroup
(n = 127) of 16.53% (95% CI, 9.6–23.39%). All the infected patients were in a chronic phase of Chagas disease: 81% with the
indeterminate form, 9.5% with the cardiac form and 9.5% with the cardiodigestive form. All patients infected with T. cruzi
had heard of Chagas disease in their country of origin, 82% knew someone affected, and 77% had a significant history of
living in adobe houses in rural areas.
Conclusions: We found a high prevalence of T. cruzi infection in immigrants from Bolivia. Detection of T. cruzi–infected
persons by screening programs in non-endemic countries would control non-vectorial transmission and would benefit the
persons affected, public health and national health systems.
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Introduction
Trypanosoma cruzi (T. cruzi) is a flagellate protozoan that causes
Chagas disease (CD). It is traditionally linked to rural areas of
continental Latin America, where it is transmitted by a variety of
bug vectors. In recent decades, the epidemiological pattern of this
disease has undergone considerable changes [1]. In the endemic
countries of Latin America, the regional Chagas programs are
working to interrupt vector-borne and transfusional transmission,
to control congenital Chagas disease and to support initiatives
aimed at improving diagnosis, management and surveillance of the
disease [2]. In non-endemic countries that receive immigrants
from Latin America or send tourists to endemic areas, CD is an
emerging disease and has become a public health problem because
it can be transmitted by non-vectorial mechanisms [3,4].
Spain is a major European host country for people from Latin
America. According to the Spanish National Institute of Statistics,
in 2009 more than 1.8 million immigrants from Latin America
were registered, accounting for 3.85% of the total population [5].
In recent years several studies of CD in non-endemic countries [6–
9] have focused in particular on non-vectorial transmission
mechanisms such as pregnancy and childbirth [10,11], blood
transfusion [12,13] and organ transplantation [14,15]. However,
when reviewing the literature we found little information on
imported CD in non-endemic countries at the primary care level
[16], which is ideal for screening the general population [17].
The clinical manifestations of chronic T. cruzi infection include
the latent form (the indeterminate chronic form), which occurs in
60% of cases [18], the cardiac form [19], the digestive or
cardiodigestive form, and sudden death [20]. Therefore, many
www.plosntds.org 1 April 2011 | Volume 5 | Issue 4 | e1135
diagnoses of CD are based on epidemiological suspicion rather
than clinical signs and symptoms.
The objectives of the present study were (1) to assess the
prevalence of Trypanosoma cruzi infection in the adult Latin
American population treated at a health center in Barcelona,
Spain; (2) to analyze the clinical phase of the disease; and (3) to
determine whether screening for imported CD in primary care
should be recommended.
Methods
Study design and scope
We performed an observational, cross-sectional prevalence
study at the health center of the Clot district, Barcelona. This
center serves a population of 25442 people, with a total foreign
population of 13.5% and a Latin American population of 6.3%
(according to the 2008 census of the Barcelona City Council) [21].
The staffs participating in the study were 14 general practitioners,
13 nurses, 1 gynecologist and 1 midwife.
Ethical conduct
The study protocol was approved by the Ethical Committee of
the Jordi Gol Institute for Research in Primary Care of the Institut
Catala` de la Salut (Catalan Health Institute).
Written informed consent was requested from all participants.
When participants were children, their parents/guardians provid-
ed informed consent.
Patients
During the period October 2007 to October 2009, all patients
from continental Latin America under 14 years of age who
presented at the health center for any health reason were invited to
participate in the study. After obtaining informed consent, we
collected clinical and epidemiological data.
We ascertained the reasons why the patients visited their
doctor/nurse by reviewing the electronic patient charts. On a
patient’s first visit to a primary care centre the Preventive Activities
and Health Promotion Program (PAPPS) is initiated [22], and at
the Clot health center this program included CD screening of all
persons originating from continental Latin America.
Serological techniques
Serological screening was performed with an immunochroma-
tographic test (ICT) that uses recombinant antigens of T. cruzi
(TcD, TcE, PEP-2 and SAPA) on whole blood collected by finger
prick.
If the screening was positive, a venous blood sample was
collected to confirm the diagnosis at the Parasitology Laboratory
of the Faculty of Pharmacy, University of Barcelona. We used 2
enzyme-linked immunosorbent assay (ELISA) methods: a conven-
tional, in-house ELISA (cELISA) with whole T. cruzi epimastigote
antigens [23] and a commercial kit with the recombinant antigens
TcD, TcE, PEP-2 and TcLo1.2 (rELISA).
In accordance with international criteria established by the
World Health Organization, sera that were reactive in two
serological methods were considered positive [24]. Positive results
were confirmed by a third ELISA using T cruzi lysate (Ortho-
Clinical Diagnostics) (oELISA). In a subsample of 101 patients we
performed the ELISA serologies (cELISA and rELISA) regardless
of the result of the ICT, in order to test the usefulness of this test in
screening for CD in primary care [25].
Management of patients
All patients infected with T. cruzi were referred to the Tropical
Medicine Unit of Hospital Clı´nic de Barcelona and clinically
evaluated by a complete review of the epidemiologic history and
consistent symptoms/signs, a general physical examination and an
electrocardiogram. If the electrocardiogram was pathologic, it was
assessed with an echocardiogram or 24-hour Holter according to
the disease detected. If symptoms consistent with gastrointestinal
involvement were detected [26], an esophageal, gastric and
duodenal transit assessment or a barium enema was performed.
Benznidazole (5 mg/kg/day for 60 days) was offered to all patients
aged 18–50 years without advanced Chagas cardiomyopathy and
no other contraindication for start benznidazole (pregnancy,
severe renal or hepatic insufficiency [27]. None of them refused
to start it.
Statistical calculations
The sample size was calculated for an alpha level of 0.05 and a
precision of 60.05% in a bilateral comparison, assuming
maximum uncertainty (50% prevalence); for a population of
1516 subjects [28] a random sample of 758 was necessary.
The programs SPSS version 17.0 and Epidat version 3.1 were
used for the statistical analysis. The x2 test was used to compare
hypotheses of independence between two categorical variables and
the Student t test for continuous variables. The confidence interval
for all hypothesis comparisons was 95% and the tests were 2-tailed.
Results
A total of 766 persons from continental Latin America were
included in the study. The epidemiological data are presented in
Table 1 and the countries of origin in Table 2.
Of the 766 patients analyzed, 27 were reactive to the ICT and
20 of these were reactive in cELISA, rELISA and oELISA. Also, 2
patients of the 101 tested by ICT, cELISA, and rELISa regardless
of the result of the first were reactive in cELISA and rELISA. Both
were also positive in oELISA, so they were considered positive.
Author Summary
Chagas disease is a parasitic infection caused by the
protozoan Trypanosoma cruzi, and is becoming an
emerging health problem in non-endemic areas because
of growing population movements. The clinical manifes-
tations of chronic T. cruzi infection include the latent form
(the indeterminate chronic form), the cardiac form, the
digestive or cardiodigestive form, and sudden death.
Therefore, many diagnoses of Chagas disease are based
on epidemiological suspicion rather than on clinical signs
and symptoms. This study showed that the prevalence of
Chagas disease in Latin American patients attending at a
health center in Barcelona is 2,87% and the highest
prevalence was found among Bolivian patients (16,53%).
All the infected patients were in a chronic phase of Chagas
disease. Detection of T. cruzi–infected persons by screen-
ing programs in non-endemic countries would control
non-vectorial transmission and would benefit the persons
affected, public health and national health systems. The
data obtained in this study and the experiences described
elsewhere suggest that it is advisable to perform Chagas
disease screening in non-endemic countries on all patients
from continental Latin America who: (1)have a suggestive
epidemiologic history, (2)are pregnant, (3)are immunosup-
pressed, (4)have symptoms suggestive of Chagas disease,
or (5)request screening.
Chagas Disease in Barcelona, Spain
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A total of 22 patients were diagnosed with CD, corresponding to
a prevalence of 2.87% (95% CI, 1.6–4.12%) in the sample studied.
Of these, 21 were from Bolivia; the prevalence of CD in the
subgroup of Bolivian patients studied (n = 127) was 16.53% (95%
CI, 9.6–23.39%). The remaining patient was from Paraguay.
All the patients infected by T. cruzi were in the chronic phase of
CD. The clinical form and the reasons why they visited the health
center are presented in Table 3. Four patients (18.2%) had been
previously diagnosed in the country of origin, but none of them
mentioned it in the primary care visit because they thought it was
a health problem proper to their country that would be unknown
to the Spanish health staff (this information was obtained when
they were asked for informed consent to participate in the study).
None of them were aware of their clinical phase and 2 patients had
received incomplete treatment.
Discussion
The prevalence of T. cruzi infection in the sample studied was
2.87% and in the subgroup of Bolivian patients it was 16.53%. In
the medical literature we found few studies of similar character-
istics to ours (involving screening of the adult Latin American
population in primary care) and their results varied [29,12] due to
the heterogeneity of the populations analyzed and the distribution
of CD in Latin America.
The laboratory confirmation of a clinical suspicion of CD is
based on consistent results of at least 2 different immunological
tests [24]. ICTs are attractive in primary care because they are
easy to use in routine clinical practice and do not require
sophisticated facilities or specialized staff. In the substudy that we
performed in 101 patients [25], for the ICT used we found a
sensitivity of 92.5% and a specificity of 96.8%. Other studies have
evaluated the sensitivity and specificity of ICTs [30,31] with
similar results. The current sensitivity of ICTs must be increased
so that they can be used as effective screening tests. Meanwhile,
they should be combined with other methods that offer greater
sensitivity [25,31].
The highest prevalence was found among Bolivian patients, in
agreement with other studies performed in Spain [9,16] and other
non-endemic countries [12,32]. No cases were diagnosed among
the Peruvian or Ecuadorian patients, who formed 45% of the
sample, probably due to the heterogeneous distribution of CD in
endemic countries and the lower seroprevalence of T. cruzi
estimated in Peru (0.69%) and Ecuador (1.74%) [33].
An epidemiologic history of having lived in rural areas and/or
adobe houses showed a significant relationship with T. cruzi
infection, consistent with the dominant vector-borne transmission
mechanism in the countries of origin. All patients with T. cruzi
infection had heard of CD in their countries of origin and
approximately 82% knew someone who was affected. These data
should be taken into account for establishing CD screening criteria
in immigrants from endemic zones, because mere knowledge of
the disease may be considered as an indirect indicator of its
presence in the region of origin.
In non-endemic countries CD screening programs have been
aimed at particularly susceptible groups: in blood banks (France
[34], the USA [35] and Spain [36]), and in pregnant Latin
Table 1. Epidemiologic data.
Variables Without CD n=744 With CD n=22 p, statistical significance
Men
Women
296 (39.8%)
448 (60.2%)
10 (45.45%)
12 (54.5%)
Not statistically significant (NS)
Age; years (SD) 36.43 (12.2) 39.86 (9.88) NS
Journeys to country of origin in last 12 months Yes 303 (40.7%)
No 441 (59.3%)
Yes 6 (27.27%)
No 16 (72.73%)
NS
Had lived in rural areas Yes 248 (33.3%)
No 496 (66.7%)
Yes 17 (77.22%)
No 5 (22.73%)
p,0.001
Had lived in adobe houses Yes 166 (22.3%)
No 578 (77.7%)
Don’t know —
Yes 17 (77.3%)
No 4 (18.2%)
Don’t know 1(4.5%)
p,0.0001
Had received transfusion in country of origin Yes 53 (7.1%)
No 691 (92.9%)
Yes 3 (13.64%)
No 19 (86.36%)
NS
Had heard of CD in country of origin Yes 317 (42.6%)
No 427 (57.4%)
Yes 22 (100%)
No 0 (0%)
p,0.0001
Knew someone with CD Yes 89 (12%)
No 655 (88%)
Yes 18 (81.81%)
No 4 (18.19%)
p,0.0001
doi:10.1371/journal.pntd.0001135.t001
Table 2. Countries of origin.
Country Total n=766 (%) Infected by T. cruzi n=22 (%)
Peru 173 (22.9)
Ecuador 171 (22.3)
Bolivia 127 (16.6) 21 (95.45)
Colombia 102 (13.3)
Argentina 63 (8.2)
Venezuela 31 (4)
Brazil 23 (3)
Chile 22 (2.9)
Paraguay 19 (2.5) 1 (4.55)
Uruguay 14 (1.8)
Honduras 12 (1.6)
El Salvador 5 (0.5)
Mexico 2 (0.2)
Guatemala 1 (0.1)
Panama 1 (0.1)
doi:10.1371/journal.pntd.0001135.t002
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American women and their neonates (the Spanish autonomous
communities of Catalonia [37] and Valencia [38]). In our study
only 9.5% of the patients with T. cruzi infection had visited the
health center due to clinical symptoms suggestive of CD. As it is a
silent disease that has recently appeared in non-endemic countries,
we stress the importance of establishing in these countries health
screening programs based on compatible epidemiologic history
among the general immigrant population from endemic areas.
These programs should be multidisciplinary [3], supported by the
best scientific evidence possible, and promoted by the health
authorities.
In non-endemic countries, detecting persons infected by T.
cruzi is important in order to control the transmission (vertical, by
transfusion, or by organ transplant), reduce reactivations in
immunodepressed persons, and delay the onset of the chronic
cardiac form through antiparasite treatment [39], all of which
have a great impact on the persons affected, on public health, and
on health systems. Nevertheless, the best solution for CD is a
combination of treatment and prevention in endemic countries
[40,41], where many programs and initiatives are underway
[2,42].
The data obtained in this study and the experiences described
elsewhere [4,12,14,16,20,27] suggest that it is advisable to perform
CD screening in non-endemic countries on all patients from
continental Latin America who: (1) have a suggestive epidemio-
logic history (having lived in a rural area, in adobe houses or
having knowledge of CD in the country of origin), (2) are pregnant,
(3) are immunosuppressed, (4) have symptoms suggestive of CD, or
(5) request screening.
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